Panel of experts: Professor Rüdiger Hehlmann Founder and coordinator European LeukemiaNet / Founder and chair ELN Foundation and former Chief of Medicine at the Mannheim Medical Faculty, University of Heidelberg (Germany) Dr Ilaria Pagani Dr Ilaria Pagani, Affiliate Senior Lecturer University of Adelaide/SAHMRI (Australia)

Program:
Clinical overview (Rüdiger Hehlmann)

• COVID-19 and CML (Rea, Breccia et al., S154)
• Personalized management and the new ELN Recommendations for treating CML (Hochhaus, Cortes et al, S153 / Saußele et al, S152)
• Monitoring MRD in CML: New developments (Cross)
• CML Genomics and the HARMONY PLUS project (Branford)

Biological overview (Ilaria Pagani)

• Spotlight talk on Leukaemic stem cells (LSC's) on metabolism (Jones)
• Response, resistance and treatment-free remission in CML
  • Mitochondrial DNA mutations are associated with response to imatinib in chronic myeloid leukemia patients (Pagani, S151)
  • Loss of G0/G1 switch gene 2 (G0S2) in CML promotes TKI resistance by deregulating the mitochondrial electron transport chain (Gonzalez, S150)

Q&A Session